Websites that explain the science without diluting it.
We are a biotech web design agency working with research-led companies across Europe. A biotech site has to satisfy three audiences at once — scientific peers, potential partners and investors — and biotech website design fails when it flatters one and loses the other two.
The hard part of a biotech website is not the visual language. It is deciding how much science goes on the page before a specialist stops trusting it, or a non-specialist stops reading.
A biotech website is read by scientific peers judging the approach, partners judging whether the platform is licensable, and investors judging whether the story holds. Each wants a different depth of the same information.
Corporate biotech websites, pipeline and technology presentation, publication repositories, scientific illustration, investor material, brand identity and the international visibility work around them.
Writing or reviewing the science itself, and advising on clinical or regulatory strategy. We structure and present what your scientific team validates, and we do not assert claims on your behalf.
Work with metabolomics, diagnostics and immunotherapy companies, in production. A biotech web design agency is judged on whether the evidence is reachable, so these figures are about scientific content and how much of it a site can carry.
A metabolomics service company, a rare-disease programme and a CRO are all biotech, and none of them convinces its buyer the same way. Our biotech web design work starts from that difference.
What research-led companies ask before starting a website project.
Enough that a specialist can evaluate the approach without contacting you, layered so a non-specialist is not blocked at the first paragraph. In practice that means a clear summary level, a technical level below it, and the underlying publications reachable from both.
Usually yes, though not in the way most founders expect. Investors check whether the public story matches the deck and whether the underlying science holds up under scrutiny. The work is normally about consistency and evidence across every page, rather than about making the site look more polished for its own sake.
Yes. We have built filterable repositories holding well over a hundred papers, structured so entries update automatically from external sources rather than requiring manual entry. That keeps the library current and searchable without becoming an ongoing maintenance burden for your scientific team, who can focus on the science itself.
Yes, and it is worth planning early. We have migrated a company to a new domain with path-preserving redirects, Search Console handover, crawl verification and backlink follow-up, so the visibility the old domain had built did not reset to zero.
Your team owns the science. We structure it, edit it for a mixed audience and design how it is presented. We do not make scientific claims on your behalf, and anything that asserts something about your data goes back to you for validation.
English is the default for biotech sites, since investors, partners and regulators reading them are mostly international audiences rather than a local market. We add other languages only when there is a concrete commercial or patient-facing reason — a local trial, a distributor, a public health programme — not as a blanket translation exercise that adds maintenance without adding reach.
A corporate site for a research-led company, a publication repository, a rebrand after a spin-out, or material for a funding round. Tell us the context and we will tell you how we would approach the biotech web design work.